Only through cooperation can win-win results be achieved. In the future, multilateral cooperation among pharmaceutical enterprises may become a trend

[pharmaceutical network market analysis] in recent years, with the change of domestic industrial environment and the adjustment of international industrial pattern, the situation of pharmaceutical industry reshuffle and layoff has become more and more intense, resulting in the current, the market elements in the industry are constantly recombined However, the degree of mutual connection and interdependence between pharmaceutical enterprises continues to deepen, and the phenomenon of "you have me in you, I have you in me" may accelerate to replace the traditional practice of old and dead incommunicado between pharmaceutical enterprises in the past era At present, a large number of R & D companies continue to focus on their own R & D end After products come out, they will basically cooperate with companies with existing marketing platforms, and the situation that production will not be self built is becoming a common phenomenon in the industry For example, a marketing enterprise obtains a product from a cro company, lands a production enterprise through MAH system, and then markets the product itself A series of operations have realized close cooperation among cro, CMO and CSO
In fact, there are many such examples For example, in 2016, Petrochemicals Group and Teva entered the U.S and EU markets through patent authorization; in the earlier period, Petrochemicals Group invested 200 million yuan to carry out the domestic market development of four kinds of new drugs "elemene injection" with Yuanda and the clinical research and new research of one kind of new drug "- elemene injection" in China and the U.S Application for listing of drugs For another example, step has cooperated with Sihuan pharmaceutical in sales agency of Guhong injection and troxerutin cerebroprotein hydrolysate injection This is mainly due to the uneven distribution of resources among pharmaceutical enterprises Some of them may have strong production capacity and advanced technology, so they focus on production; some of them have weak sales capacity or weak promotion ability in a certain field, so they entrust this variety to the sales team of industrial enterprises with strong promotion ability in this field But in addition, there are also some enterprises to enhance the R & D innovation ability, strengthen the market competitiveness, and actively form close cooperation with other pharmaceutical enterprises For example, Jiuzhou pharmaceutical said on the collective reception day of investors in 2019 that the company and Novartis, Gilead, zoetis, Roche, Sandoz, Mylan, Teva, Meiji and other international pharmaceutical giants have established close cooperation relations, and formed close cooperation partners with dozens of well-known new drug research and innovation companies, such as China green leaf pharmaceutical, Hualing pharmaceutical, and Ellis pharmaceutical, and formed deep embedded cooperation relations with well-known domestic pharmaceutical companies Northeast Pharmaceutical said in the near future that it would set up product pipelines and teams in the short term through licensing and introduction In addition, Shanghai Pharmaceutical has been adhering to the concept of cooperative development for many years, and has successively cooperated with many universities, hospitals and scientific research institutes, effectively enhancing the company's scientific and technological innovation vitality In general, multilateral cooperation of pharmaceutical enterprises is a business model exploration and evolution under the reallocation and integration of resources We may not be able to strictly distinguish whether an enterprise is a manufacturing enterprise or CRO, CMO, VC or CSO They may become a normal, logical and market-oriented business model in the future Therefore, some insiders also say that in the future, most enterprises can get combination opportunities and means in more fields and directions Whoever has a good combination will win, and who is likely to become a winner in the industry tide.